Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728582 · ClinicalTrials.gov registry record · NA
Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy
A NA study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT03728582: Completed NA study, sponsored by Johns Hopkins University.
NCT03728582 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03728582, a NA study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
People with Primary Progressive Aphasia (PPA) are is a debilitating disorder characterized by the gradual loss of language functioning, even though cognitive functioning is relatively well preserved until the advanced stages of the disease. There are very few evidence-based treatment options available. This study investigates the behavioral and neural effects of multiple consecutive tDCS sessions paired with language therapy targeting verbs in sentences with individuals with PPA.
Interventions
- DEVICE Active tDCS plus Speech-Language Therapy
- DEVICE Sham tDCS plus Speech-Language Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-10-10 |
| Est. Completion | 2022-03-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03728582
The ClinicalTrials.gov registry entry for NCT03728582 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Active tDCS plus Speech-Language Therapy is the first listed.
NCT03728582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03728582 about?
NCT03728582 is a clinical study titled "Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy". People with Primary Progressive Aphasia (PPA) are is a debilitating disorder characterized by the gradual loss of language functioning, even though cognitive functioning is relatively well preserved until the advanced stages of the disease. There are very few evidence-based treatment options availab...
What is the current status of trial NCT03728582?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2018-10-10. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT03728582?
The interventions under investigation include: Active tDCS plus Speech-Language Therapy (DEVICE), Sham tDCS plus Speech-Language Therapy (DEVICE).
Who is sponsoring clinical trial NCT03728582?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.